No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

By J. Molina, C. Delaugerre, J. L. Goff, Breno Mela-Lima, D. Ponscarme, L. Goldwirt, N. De Castro. Médecine et maladies infectieuses, 2020

759 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19 (2020, methodology): “Subsequent studies have not identified a similar benefit of hydroxychloroquine in Covid-19 [2] [3] [4] [5] and concerns have been raised about the original positive study.”
Immunology of COVID-19: Current State of the Science (2020, neutral): “In a prospective study of 11 patients who had received 600 mg HCQ over 10 days with AZ on days 1-5, there were several patients with worsening clinical status and one death; 8/10 patients had a positive PCR result on day 10 ( Molina et al., 2020) .”
Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions (2020, neutral): “At the time of writing this review, seven articles are reporting clinical data (observational studies or clinical trials), with either positive (n=4) [189] [190] [191] [192] or negative (n=5) results [193] [194] [195] [196] , but no definitive conclusions can currently be drawn because of major bias”
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 (2022, background): “1 high risk for clinically relevant arrhythmias for this treatment [15, 16].”